1606973-52-7Relevant articles and documents
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders
Gurney, Mark E.,Nugent, Richard A.,Mo, Xuesheng,Sindac, Janice A.,Hagen, Timothy J.,Fox, David,O'Donnell, James M.,Zhang, Chong,Xu, Ying,Zhang, Han-Ting,Groppi, Vincent E.,Bailie, Marc,White, Ronald E.,Romero, Donna L.,Vellekoop, A. Samuel,Walker, Joel R.,Surman, Matthew D.,Zhu, Lei,Campbell, Robert F.
, p. 4884 - 4901 (2019/05/16)
Novel pyridine- and pyrimidine-based allosteric inhibitors are reported that achieve PDE4D subtype selectivity through recognition of a single amino acid difference on a key regulatory domain, known as UCR2, that opens and closes over the catalytic site f
